Price$1.81+0.02 (+1.12%)
06:15 PM06:45 PM
News · 26 weeks44+33%
2026-01-182026-07-12
Mix3490d
- Insider19(56%)
- SEC Filings8(24%)
- Other5(15%)
- Earnings2(6%)
Latest news
25 items- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 4,410 shares, increasing direct ownership by 7% to 64,396 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERSEC Form 3 filed by new insider Blacher Joshua3 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERGeneral Counsel and Corp Sec Eylward Susan was granted 920 shares and sold $1,730 worth of shares (920 units at $1.88) (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERChief Medical Officer Faller Douglas Vincent was granted 1,308 shares, increasing direct ownership by 6% to 23,204 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERPresident and CEO Lindborg Stacy was granted 2,534 shares, increasing direct ownership by 3% to 76,722 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- SECImunon Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- INSIDERChief Medical Officer Faller Douglas Vincent was granted 21,896 shares (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERGeneral Counsel and Corp Sec Eylward Susan was granted 14,696 shares and sold $20,674 worth of shares (11,800 units at $1.75) (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 42,519 shares, increasing direct ownership by 243% to 59,986 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERPresident and CEO Lindborg Stacy was granted 67,150 shares, increasing direct ownership by 954% to 74,188 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- PRLife Sciences Virtual Investor Forum Presentations Now Available for On-Demand ViewingNEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing. REGISTER AND VIEW PRESENTATIONS HERE Select companies are accepting 1x1 management meeting requests through June 19th. Please Schedule 1x1 Meetings here. The presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Presenting Companies CompanyTicker(s)MetaVia Inc.(NASDAQ:MTVA)Nasus Pharma Ltd.(NYSE:NSRX)CytoSorbents Corporation(NASD
- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 4,629 shares, increasing direct ownership by 36% to 17,467 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERPresident and CEO Lindborg Stacy was granted 1,803 shares, increasing direct ownership by 34% to 7,038 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- PRLife Sciences Virtual Investor Forum Agenda Announced for June 24th & 25thNEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings
- PRIMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without ModificationOn track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer Novel immunotherapy technology demonstrating unprecedented IL-12 safety profile and extraordinary Phase 2 efficacy LAWRENCEVILLE, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the independent Data Monitoring Committee (iDMC) has recommended continuation of the pivotal Phase 3 OVATION 3 clinical trial evaluating IMNN-001 in combination with standard of care (SoC) neoa
- PRIMUNON to Present at the Life Sciences Investor Forum on June 25thLAWRENCEVILLE, N.J., June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON, will present at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on Thursday, June 25, 2026, at 12:00 p.m. ET. DATE: Thursday, June 25th, 2026TIME: 12:00 p.m. ETWebcast Registration Link HereAvailable for 1x1 meetings: Schedule 1x1 Meetings HERE This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event liv
- SECSEC Form S-8 filed by Imunon Inc.S-8 - Imunon, Inc. (0000749647) (Filer)
- SECSEC Form 8-K filed by Imunon Inc.8-K - Imunon, Inc. (0000749647) (Filer)
- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 4,089 shares, increasing direct ownership by 47% to 12,838 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERPresident and CEO Lindborg Stacy was granted 1,593 shares, increasing direct ownership by 44% to 5,235 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- SECImunon Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- PRIMUNON Announces Up to $10 Million Cash FinancingIncludes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports IMUNON's Highly Anticipated Phase 3 OVATION 3 Study of IMNN-001 in advanced ovarian cancer LAWRENCEVILLE, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company has entered into definitive agreements with expected aggregate gross proceeds to the Company in the amount of $10 million. The transaction includes 250 shares of non-redeemable, non-convertible preferred stock for $2.5 million and two secured pr
- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 3,484 shares, increasing direct ownership by 66% to 8,749 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERDirector Pellizzari Christine A was granted 5,557 shares, increasing direct ownership by 215% to 8,142 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERDirector Dentzer James E was granted 11,148 shares, increasing direct ownership by 292% to 14,963 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
IMNN FAQ
4 questionsWhere does IMNN stock trade?
Imunon Inc. (IMNN) is listed on NASDAQ.What sector and industry is IMNN in?
Imunon Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to IMNN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IMNN side-by-side with any of them on Quantisnow.How can I track IMNN on Quantisnow?
Quantisnow aggregates Imunon Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMNN to receive live email and push alerts on every new disclosure.